SS18 and synovial sarcoma: The effectiveness of SUMO2 inhibition in synovial sarcoma models by specifically suppressing the pathogenic features of the SS18::SSX fusion oncoprotein indicate that SUMO2 is a highly selective vulnerability in synovial sarcoma as indicated by our analysis of the Dependency Maps (DepMap) data.